Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628626 · ClinicalTrials.gov registry record · Phase 3
A Study of Colesevelam in Fecal Incontinence
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 88
- Enrollment target
NCT02628626: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT02628626 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02628626, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 88 participants
- Enrollment target
Study Summary
Compare the effects of a combination of colesevelam and clonidine to placebo on bowel symptoms in patients with urge or combined type of FI.
Interventions
- OTHER Placebo
- DRUG Colesevelam
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2015-11 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02628626
The ClinicalTrials.gov registry entry for NCT02628626 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02628626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02628626 about?
NCT02628626 is a clinical study titled "A Study of Colesevelam in Fecal Incontinence". Compare the effects of a combination of colesevelam and clonidine to placebo on bowel symptoms in patients with urge or combined type of FI.
What is the current status of trial NCT02628626?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2015-11. Estimated completion is 2022-04-14.
What interventions are being tested in trial NCT02628626?
The interventions under investigation include: Placebo (OTHER), Colesevelam (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT02628626?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.